UK Allied Health Professor Receives Patent On Using Lithium With AIDS Drugs

January 06, 1999

University of Kentucky College of Allied Health Professions Associate Dean for Research Vincent S. Gallicchio, Ph.D., has received a patent to test whether current and future anti-viral drug agents can be made more effective when made chemically as a lithium salt.

Lithium is known to have a number of immune enhancing properties and could possibly protect certain cells from toxic therapies. Gallicchio proposes that combining drugs commonly used for AIDS patients with lithium salts could result in fewer toxic side effects and reduce the amount of virus in a person's system by enhancing the immune system.

The drugs, AZT and DDI, currently cause toxic side effects to bone marrow and the pancreas. When these side effects occur, patients either have to take a smaller amount of the drug or stop treatment. The second effect could be that the lithium could cause certain cells with the AIDS virus to die.

"It will remain to be determined whether these new drugs will actually reduce the amount of infectious virus by inhibiting a process that is essential for viral life-cycle," Gallicchio said.

The clinical trials for this study will start this year at the University of Potchefstroom in South Africa. The new treatment is being tested in South Africa because AIDS infects a new person there every 11 seconds. The patent is filed in the United States, Europe, and Africa.
-end-


University of Kentucky Medical Center

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.